Cargando…
Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
Current clinical and observational evidence supports the EXTREME regimen as one of the standards of care for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) followed by the administration of immune checkpoint inhibitors (ICIs). In addition to the inhibition of the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161653/ https://www.ncbi.nlm.nih.gov/pubmed/37143088 http://dx.doi.org/10.1186/s13046-023-02691-4 |